In the context of recent episodes of cases of monkeypox virus (MPXV) infection occurring outside endemic African areas, the HCSP proposes preventive measures to be implemented to prevent the transmission of MPXV by blood products, grafts and other products and elements of the human body (PCH).
In view of the data available on the modes of transmission of MPXV, diagnostic methods, persistence of MPXV in the human body, virus inactivation processes and international recommendations, the HCSP recommends:
1) For contact persons who have received the Imvanex© vaccine, exclusion from PCH donation for a period of 4 weeks following the last dose of vaccine
2) For donors of blood and organs, tissues, cells:
- A 21-day deferment to donation for people identified as contact cases
- A 42-day donation deferment for people with confirmed MPXV infection
However, these recommendations take into account specific situations requiring:
- In the event of a vital emergency (heart and liver) for organ donations from donors with a confirmed, probable or suspected infection, to carry out an orthopoxvirus PCR on blood, subject to being able to provide the result within the deadlines and assess the benefit/risk ratio on a case-by-case basis,
- If it is impossible to postpone a hematopoietic stem cell transplant, to be able to have the result of an orthopoxvirus PCR on blood,
- In the presence of elements in favor of MPXV infection in deceased donors, to exclude them definitively from the donation of organs, tissues or cells.
3) For medically assisted procreation, people who have had a confirmed MPXV infection are adjourned 42 days from the date of onset of clinical signs and those identified as contact cases are adjourned 21 days from the date of last contact.
For the preservation of fertility, the sample is postponed whenever possible or otherwise frozen (an orthopoxvirus PCR test will be performed at the time of thawing).
